CR Pharmaceutical's pharmaceutical manufacturing business involves chemicals, TCM, biological preparations and nutritional health products. The product portfolios cover a series of therapeutic fields with good growth potential, such as cardiovascular, gastrointestinal and metabolism, high-volume intravenous infusion, pediatrics, and respiratory system. By December 31, 2021, our pharmaceutical manufacturing business had produced a total of 615 pharmaceutical products, of which 335 had been included in the Catalog of Medicines Covered by National Medical Insurance System and 145 included in the National Essential Medicine List.
CR Sanjiu has ranked first in the China Non-Prescription Drug Product Comprehensive Statistical Ranking released by the China Non-Prescription Drug Association for five consecutive years. The Dong-E-E-Jiao has been certified as a product under international geographical indications protection, and its manufacturing process has been recognized as China's intangible cultural heritage. It has been listed in the "Top 50 Chinese Brands" by Interbrand for two consecutive years.
In addition, we make constant efforts to upgrade intelligent manufacturing and improve automation, so as to continuously improve quality and efficiency. Both CR Sanjiu and Dong-E-E-Jiao were selected as the Pilot Demonstration Plant of Intelligent Manufacturing by the Ministry of Industry and Information Technology (MIIT) in 2021, setting a demonstration benchmark for intelligent manufacturing in the pharmaceutical industry. In CR Sanjiu, the new model application project on intelligent manufacturing of the TCM formula granules, the new model application project on the digital workshop of TCM preparation, and the project on the whole industry chain digital manufacturing technology of TCM injection were accepted by the MIIT, and the technology applicability research and the whole-process quality control system project passed the acceptance of the Ministry of Science and Technology. CR Double-Crane successfully realized the joint upgrade of production, sales and logistics by advancing the process of online business, and applied industrial Internet technology to successfully pilot the construction of automated workshops, thus increasing production capacity. CR Jiangzhong completed the implementation of the equipment management system, and developed a quantitative assessment APP, marking that it realized the visualized and standardized equipment and spare parts management. Committed to upgrading of equipment technology, Dong-E-E-Jiao realized the upgrading of digital quality inspection of product manufacturing lines through the application of AI technology. In 2021, the preparation plant of CR Zizhu in Beijing was selected as a national green plant, and CR Double-Crane was selected as a green supply chain management enterprise by the MIIT.
We implement the Healthy China initiative and drive development based on innovation and quality. We secure drug safety and equitable pricing, and constantly promote the application of innovation achievements. By providing high-quality healthcare solutions, we are dedicated to bringing affordable and accessible healthcare products and services to more people.
